Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.

Biogen announced a $1 billion acquisition of RayThera, a company with anti-inflammatory assets targeting immune-mediated conditions. This strategic move strengthens Biogen's immunology portfolio following its earlier acquisition of Apellis Pharmaceuticals. The company is successfully transitioning from its declining MS drug business to growth areas like Alzheimer's and rare diseases, with early signs of business stabilization and revenue growth.

07/04/2026, 4:02 AM • The Motley Fool

Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB

A federal court has approved an $18.9 million settlement for investors who purchased Biogen Inc. common stock between June 8, 2021 and July 12, 2021. A settlement hearing is scheduled for September 29, 2026, to determine if the settlement is fair and reasonable. Class members must submit a Proof of Claim by September 24, 2026 to receive compensation.

06/29/2026, 8:00 AM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

Pomerantz LLP is investigating Biogen Inc. for potential securities fraud following the company's announcement of Phase 2 CELIA study results for diranersen (BIIB080), an Alzheimer's disease treatment. Although Biogen described the results as 'compelling,' the study missed its primary dose-response endpoint, causing the stock to fall $13.16 per share (6.43%) to $191.37 on May 14, 2026.

06/23/2026, 5:58 PM • GlobeNewswire

Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight

The cutaneous lupus erythematosus (CLE) market is projected to grow at 8% CAGR through 2036, driven by emerging targeted therapies and increased disease awareness. The market was valued at USD 650 million in 2025 across seven major markets. Key pipeline drugs from major pharmaceutical companies targeting plasmacytoid dendritic cells and type I interferon pathways are expected to transform treatment options for CLE patients.

06/22/2026, 1:00 PM • GlobeNewswire

Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline

Biogen agreed to acquire private biotechnology company RayThera for up to $1 billion to expand its immunology pipeline. The deal includes an upfront payment with the majority tied to future clinical and regulatory milestones, expected to close in Q3 2026. RayThera focuses on small-molecule therapies for immunological diseases with a lead candidate entering Phase 1 development in early Q3 2026.

06/18/2026, 11:07 AM • Benzinga

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

Denali Therapeutics announced it will sell its Rare Pediatric Disease Priority Review Voucher for $195 million following FDA approval of AVLAYAH, the first FDA-approved biologic designed to cross the blood-brain barrier. The proceeds will support advancement of Denali's clinical pipeline for lysosomal storage disorders and neurodegenerative diseases. However, the article also notes that Biogen and Denali's Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease failed to meet its primary and secondary endpoints, leading to discontinuation of the program.

06/18/2026, 8:00 AM • GlobeNewswire

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

Biogen has agreed to acquire private biotechnology company RayThera Inc. for up to $1 billion in an upfront payment plus milestone-based contingent payments. The acquisition adds multiple anti-inflammatory assets to Biogen's immunology portfolio, with RayThera's lead candidate expected to enter Phase 1 development in early Q3 2026. The transaction is anticipated to close in Q3 2026.

06/17/2026, 6:59 PM • GlobeNewswire

Biogen Stock Slides After Trial Miss, but Analysts Stay Bullish

Biogen's stock fell over 10% after its diranersen Alzheimer's drug missed the primary endpoint in the Phase 2 CELIA trial on May 14. However, the drug showed meaningful reductions in tau pathology and signs of slower clinical decline. Despite the setback, analysts remain bullish with a consensus price target of $215.62, citing the company's decision to advance the drug as a vote of confidence. Biogen's base business is supported by strong Leqembi sales growth (74% YoY to $168M) and the planned Apellis acquisition.

05/22/2026, 8:01 AM • Investing

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

Biogen and Denali Therapeutics announced that BIIB122 (DNL151), a LRRK2 inhibitor, failed to meet primary and secondary endpoints in the Phase 2b LUMA study for early-stage Parkinson's disease. The companies will discontinue development in idiopathic Parkinson's disease, though Denali will continue the Phase 2a BEACON study in LRRK2 variant carriers. The drug demonstrated acceptable safety and >90% kinase inhibition but did not slow disease progression.

05/21/2026, 6:00 PM • GlobeNewswire

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

Biogen and Denali Therapeutics announced that BIIB122 (DNL151), an investigational LRRK2 inhibitor, failed to meet primary and secondary endpoints in the Phase 2b LUMA study for early-stage Parkinson's disease. The drug did not slow disease progression compared to placebo. Both companies will discontinue development of BIIB122 in idiopathic Parkinson's disease, though Denali will continue the Phase 2a BEACON study in LRRK2 variant carriers with data expected in H1 2027.

05/21/2026, 6:00 PM • GlobeNewswire

Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Over 50 pharmaceutical companies are advancing 55+ pipeline drugs for pulmonary arterial hypertension (PAH) treatment. Recent developments include United Therapeutics' ralinepag meeting Phase III endpoints with 55% risk reduction, Gossamer Bio's seralutinib Phase III results, GSK's acquisition of 35Pharma for HS235, and Inhibikase Therapeutics enrolling patients in Phase III IMPROVE-PAH trial. Multiple novel mechanisms of action are being explored to address persistent clinical gaps in PAH management.

05/19/2026, 1:00 PM • GlobeNewswire

Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment

The global protein synthesis research market is experiencing accelerating growth driven by increased investment in cell and gene therapy research, rising chronic disease prevalence, and expanding healthcare budgets. North America leads with 42.8% market share, while Asia-Pacific infrastructure expansion presents significant growth opportunities. Key market drivers include strong late-stage therapy pipelines and government support through initiatives like the CHIPS and Science Act.

05/18/2026, 2:33 PM • GlobeNewswire

Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight

The oligonucleotides clinical trial landscape is expanding rapidly with 200+ companies developing 600+ pipeline drugs. Major players like Novartis, Alnylam Pharmaceuticals, Amgen, and WaVe Life Sciences are advancing promising therapies across various clinical stages. Approximately 20+ oligonucleotides are in late-stage development while 150+ are in mid and early stages. Recent developments include SanegeneBio's $110M Series B funding, FDA approvals for multiple orphan drug designations, and several companies advancing Phase II and Phase III trials.

05/14/2026, 1:00 PM • GlobeNewswire

Dow Jones Rally Looks Fragile With Inflation Data Running Hot

The Dow Jones climbed back above 50,000 driven by Cisco's strong earnings beat and guidance raise, while Nvidia gained on news of Chinese H200 chip approvals. However, the rally appears fragile as inflation data runs hot with import prices spiking 1.9% and energy costs surging, offsetting positive consumer resilience metrics. The Trump-Xi summit in Beijing provided mild sentiment support but delivered limited concrete deliverables.

05/14/2026, 12:54 PM • Investing

Why Is Biogen Stock Falling Thursday?

Biogen stock fell 4.97% after reporting Phase 2 results for its Alzheimer's drug diranersen, which missed its primary endpoint but showed cognitive benefits and tau biomarker reductions across all doses. The company plans to advance the therapy to registrational development. Separately, Biogen completed its acquisition of Apellis Pharmaceuticals, adding two commercial drugs worth $689 million in 2025 revenue.

05/14/2026, 11:57 AM • Benzinga